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ABSTRACT  
   
Stroke remains a leading cause of adult disability in the United States.  In recent 
studies, chronic vagus nerve stimulation (VNS) has been proven to enhance functional 
recovery when paired with motor rehabilitation training after stroke.  Other studies have 
also demonstrated that delivering VNS during the onset of a stroke may elicit some 
neuroprotective effects as observed in remaining neural tissue and motor function.  While 
these studies have demonstrated the benefits of VNS as a treatment or therapy in 
combatting stroke damage, the mechanisms responsible for these effects are still not well 
understood or known.  The aim of this research was to further investigate the mechanisms 
underlying the efficacy of acute VNS treatment of stroke by observing the effect of VNS 
when applied after the onset of stroke.  Animals were randomly assigned to three groups: 
Stroke animals received cortical ischemia (ET-1 injection), VNS+Stroke animals 
received acute VNS starting within 48 hours after cortical ischemia and continuing once 
per day for three days, or Control animals which received neither the injury nor 
stimulation.  Results showed that stroke animals receiving acute VNS had smaller lesion 
volumes and larger motor cortical maps than those in the Stroke group. The results 
suggest VNS may confer neuroprotective effects when delivered within the first 96 hours 
of stroke. 
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CHAPTER 1 
INTRODUCTION 
Stroke  
Stroke continues to be a leading cause of death and a major cause of disability in 
the United States (American Stroke Association, 2019).  While the mortality rate of 
stroke has been on the decrease in recent years, a majority of stroke survivors will 
experience long term disability (Feigin et al., 2014). Thus, it is becoming increasingly 
important to continue examining new therapies that may aid in recovery from or protect 
from damage incurred by stroke.  It is particularly valuable to address ischemic stroke, as 
the majority of patients suffer from ischemic strokes (Center for Disease Control and 
Prevention, 2017).  During an ischemic stroke the blood supply to part, or all of the brain 
is obstructed.  This prevents the tissues in that area from receiving the oxygen they need 
which will lead to cell death. 
Current emergency treatment methods of ischemic stroke typically involve either 
clot-busting medication, such as tissue plasminogen activator (tPA), or intra-arterial 
therapy.  However, these options must be administered within a very limited time 
window.  tPA must be delivered within 4.5 hours (Mayo Clinic, 2019), while intra-
arterial therapy, such as mechanical thrombectomy, typically must be done within a 6 
hour time window (Abou-Chebl, 2010).  Additional limitations to tPA treatment 
eligibility include age, severity and location of stroke, as well as general health 
(American Stroke Association).   Once the effective time frame for these treatments has 
passed, the remaining option is physical therapy (motor rehabilitation) to try to aid in 
motor function recovery after the stroke has taken its course.  Fortunately, motor 
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rehabilitation has been long established as an effective way of restoring motor function 
following neural injury, and many studies have demonstrated the benefits of motor 
rehabilitation following stroke (Dimyan et al., 2011; Nudo, Barbay and Kleim, 2000). 
Rat model of stroke 
There has been some debate over the clinical relevancy of using rodents to model 
human neurological disorders due to the obvious neuroanatomical differences.  However, 
there are a multitude of reasons justifying the rat as a suitable choice to model 
neurological disorders in humans.  Rats have been studied the most out of all animal 
models of neurological diseases.  Despite the extensive amount of prior research using rat 
models, this does not compensate for the fact that there are indeed some challenges when 
modeling human neurological diseases in animals.  This is because the same disorder 
may cause different physical symptoms across species.  In spite of this, these challenges 
can be overcome by focusing on changes in function rather than physical changes 
associated with the neurological disease under study. It has been found that functionally, 
rats and primates have a lot of similarities. (Cenci et al., 2002; Kleim, Boychuk and 
Adkins, 2007) 
While there are several commonly used methods for modeling stroke (focal 
ischemia) in rats, injection of Endothelin-1 (ET-1) is recognized as a suitable model due 
to its similarities to the stroke experienced by human patients (Cenci et al., 2002).  An 
intracortical injection of ET-1, a powerful vasoconstrictor (Yanagisawa et. al., 1988), will 
reduce local blood flow for over an hour (Fuxe et al., 1997).  Cerebral blood flow (CBF) 
in the ipsilesional cortex stays depressed and does not recover to contralesional cortex 
levels until 16-22 hours.  This delayed, gradual reperfusion more closely models the 
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ischemic stroke that human patients experience in comparison to other stroke models.  In 
addition, the manner in which the infarct gradually grows is also similar to that which 
takes place in human stroke patients (Biernaskie et al., 2001). 
Vagus Nerve Stimulation 
In recent years, attention has shifted towards vagus nerve stimulation (VNS) due 
to its potential for a non-invasive treatment alternative to a variety of neural injuries and 
disorders.  The ability to non-invasively stimulate the vagus nerve in human patients has 
been proven by Clancy et al. (2014) who demonstrated a method to effectively 
transcranially stimulate the auricular branch of the vagus nerve.  As such, there is worth 
in examining the efficacy of direct VNS as a treatment for a variety of conditions in 
hopes of eventually developing a non-invasive approach with the same effect. 
 
Figure 1: Vagus nerve stimulation cuff implant.  Depiction of the relative location of the 
left vagus nerve in a rat (left) and photograph of the implant of vagus nerve stimulator 
(right) (Nichols et al., 2011) 
Vagus nerve stimulation is an approved treatment for epilepsy and there have 
been several clinical investigations of the viability of VNS in treating anxiety and 
Alzheimer's Disease, with some studies reporting some success for depression treatment 
(Daban et al., 2008; Groves et al., 2005; Sackeim et al., 2001).  There have also been a 
multitude of experiments in rats demonstrating the viability of VNS paired with 
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rehabilitation as a method of augmenting functional recovery following neural injury, 
such as stroke (Khodaparast et al., 2013; Porter et al., 2011) and traumatic brain injury 
(Hays et al.,  2013; Pruitt et al., 2016).  
Research objective  
The goal of this study was to investigate the effects of applying acute VNS 
following an ischemic stroke.  Previous studies have focused on the effects observed 
when VNS paired with rehabilitative training as a therapy  following stroke.  Some 
studies have determined that without pairing VNS with rehabilitation training, VNS alone 
is not significantly effective in motor function recovery, however it must be noted that 
these experiments were all done at a time point of one week or more following the stroke 
(Khodaparast et al., 2014; Porter, et al., 2011).  The authors of these studies believe there 
are separate mechanisms behind their findings and the neuroprotective effects reported 
when applying VNS stimulation during, or relatively soon after (within 2 hours of) the 
brain injury, postulating that the results seen when starting VNS therapy a week or more 
after the stroke are due to VNS promoting neuroplasticity (Khodaparast et al., 2016).  
Several studies investigating the efficacy of VNS during the onset of a stroke (Hiraki, et 
al., 2012; Sun et al., 2012), or shortly after—30 min after the stroke induction (Ay et al., 
2009)—have found that animals receiving VNS had smaller lesions and overall better 
functional scores, implying the presence of potential neuroprotective effects of VNS 
when applied at the time of stroke.  Yet the time period after the stroke has completed its 
course, and before rehabilitative measures begins, has still not been closely examined.  
Thus, this study aimed to address the questions of whether similar effects would still be 
observed when delivering acute VNS beginning within 48 hours after the injury. 
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CHAPTER 2 
METHODS 
Subjects 
Fifteen adult (90 days), male Long-Evans rats were assigned to one of three 
groups: Control (n=6), Stroke (n=4) or VNS+Stroke (n=5).  Animals in the VNS+stroke 
group received both a cortical ischemic stroke and VNS cuff implant on day 1, while 
animals in the Stroke group received only stroke on day 1 (see figure 2 below of 
experimental timeline).  Animals in the control group received no VNS nor stroke.  
Animals in the VNS+Stroke group were given stimulation for three consecutive days 
beginning within 48 hours after the injury.  On day 6, all animals were mapped via ICMS 
and perfused following the mapping procedure.  Throughout the entirety of the 
experimental timeline, each animal’s weights were maintained to be above a minimum of 
85% of its original weight.  All procedures involving animal subjects were approved by 
the Arizona State University Institutional Animal Care and Use Committee.  
 
Figure 2: Experimental timeline for each group 
VNS
Stroke
Control
Stroke
VNS implant
Stroke
VNS 30 min ICMS
D1
D1
D1
D2 D3 D4 D5 D6
D2 D3 D4 D5 D6
D2 D3 D4 D5 D6
VNS 30 min VNS 30 min
ICMS
ICMS
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VNS cuff electrode and connector head stage construction 
Bipolar electrode stimulation cuffs were constructed by threading platinum-
iridium (PI) wire through medical grade microtubing (Micro-Renathane 0.040” x 0.025”). 
Tubing was cut to approximately 4mm measurements and an incision made down the 
length of the tubing.  Platinum-iridium wire (Medwire .006” braided platinum iridium 
wire) was cut to lengths of approximately 6.5 centimeters. One end of each wire was 
soldered to a gold press pin and the other threaded perpendicularly through the tubing 
(see Figure 3 below).  Exposed ends were then trimmed and coated with UV cured glue 
(Loctite light cure adhesive) to eliminate any exposed, uninsulated wire along the exterior 
of the cuff.  Cuff construction methods mostly followed methods as previously reported 
in (Nichols et al., 2011; Porter et al. 2011) and protocols shared by Dr. Michael Kilgard 
and lab members at University of Texas at Dallas’ Texas Biomedical Device Center. 
However due to the lab’s past concerns regarding proper contact between the electrode 
and nerve (Hillebrand, 2018), the design used in this experiment was modified for a 
closer, more secure fit around the vagus nerve, and as such deviates from previously 
described methods in literature by using a smaller tubing (.040” x .025” rather than .08” 
x .04”). 
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Figure 3: Image of VNS cuff and head stage.  Left: magnified image of tubing cuff.  Right: 
image of full VNS cuff with leads and connector head stage. 
Two channel connector head stages were constructed by adding wire leads 
between connector pins and gold press pins.  All of the wires and exposed metal were 
then encased in acrylic and left to air-cure for at least 24 hours before testing.  All head 
stages were tested by connecting to a stimulator and verifying the signal on an 
oscilloscope. 
Each stimulation cuff was tested at two separate points in time.  Cuffs were first 
verified electrically by observing an expected output waveform when connected to both 
stimulator and oscilloscope. The tubing portion of the cuff was submerged in saline 
solution to complete circuit before turning on the stimulator.  Stimulator machine was set 
to same parameters as used in experimental stimulation (see VNS stimulation section).  
Each cuff was tested once more during surgery, at time of implant.  (see VNS cuff 
implant section).  Any stimulator cuff electrodes or head stages that generated errors were 
discarded and not used for any experiments. 
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Surgical procedures 
VNS cuff implant 
Animals were anesthetized under 5% isoflurane gas and maintained at levels 
between 1.5% and 3%.  Subjects were placed in a stereotaxic instrument to secure head at 
a level position and placed on a heating pad to help maintain body temperature of 
approximately 37.4 °C.  Animals’ blood oxygen level and heartrate were also monitored 
via pulse oximeter paw cuff (MouseSTAT Jr) throughout the surgical procedure. Implant 
procedure was similar to methods as described in previous literature (Dorr and Debonnel, 
2006; Nichols, 2011).  After anesthesia induction, the rat was laid on its back with its 
ventral side exposed.  A rostral to caudal incision was made over the left neck area, and 
muscle tissue blunt dissected to expose the carotid sheath. The carotid sheath was teased 
apart along with any facia along the nerve to completely expose the vagus nerve. The 
vagus nerve was then fit into the VNS cuff and tested.  VNS cuffs were confirmed to be 
working properly if sudden decrease in heart rate was observed upon turning on 
stimulation.  After confirming the cuff’s proper operation, the opening of the VNS cuff 
was sealed using dental filling composite (Silmet Profil flow) and cured via UV light 
gun.  The wire leads of the cuff were then tunneled subcutaneously towards an opening 
created on the dorsal side of the head.  The ventral opening was then sutured closed and 
antibiotic ointment applied over the suture line.  Upon testing, average VNS induced 
heart rate decrease was 119.2 ± 70.898 BPM. 
Cortical Ischemia 
Immediately after the cuff implant, animals were maintained under 5% isoflurane 
gas and maintained at levels between 1.5% and 3%.  For animals who received VNS 
implant, they were left on maintenance levels of isoflurane while immediately moving on 
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to the ischemia induction phase.  An anterior to posterior incision was made to expose the 
skull before creating a burr hole.  A Hamilton syringe was lowered into the burr hole to 
deliver 4µl of Endothelin-1 (prepared as 1mg/mL) as an intracranial injection.  
Endothelin-1 was injected at 1µl/min and allowed to sit for 5 minutes to allow for proper 
perfusion.  After the injection was completed and the Hamilton syringe removed 
completely, the hole was sealed with bone wax.   
Head stage placement and recovery 
Following injection of Endothelin-1, five indentations were drilled into the skull, 
all well posterior to the Endothelin-1 injection site.  Bone screws were inserted into these 
areas and acrylic used to affix the head stage over the bone screws.  The pin ends of wire 
leads were plugged into the head stage, then additional acrylic was layered  over and 
around the head stage to ensure sturdy fixation.  After allowing the acrylic to set and 
confirming stable bonding, the opening around the head stage was sutured closed and 
antibiotic ointment applied over the suture line. 
At the completion of surgery, all animals were given 4.0cc ringers and 0.03cc 
buprenorphine (Buprenex 0.3mg/mL) and allowed to recover for several minutes on the 
heating pad before being returned to the home cage. 
VNS Stimulation 
48 hours following the initial surgery, unanesthesized animals were given 30 
minutes of vagus nerve stimulation for three consecutive days.  VNS was delivered at 
1Hz, 500ms train of 15 pulses (0.8mA).  During stimulation, animals were monitored and 
allowed to do as they pleased and move freely within the cage space.  
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Motor cortex mapping (Intracortical Microstimulation) 
Animals were anesthetized with an IP injection of ketamine hydrochloride 
(approximately 90mg/kg). Animals were also given 0.15cc xylazine (AnaSed, 20mg/mL, 
IP) approximately 5 minutes following the injection of ketamine.  A craniotomy was 
performed on the left hemisphere and dura removed to expose rostral and caudal forelimb 
areas of the motor cortex. 
Following methods similar to (Kleim, Barbay, and Nudo, 1998; Warraich, 2013 ), 
a 500µm grid was superimposed over an image taken of the exposed cortex.  Using a 
hydraulic microdrive, a glass microelectrode was lowered (approximately 1550µm) at 
points along the grid lines.  At each site the current was gradually increased (£60µA) 
until a movement was elicited and both the movement type and threshold recorded.  If no 
movement was observed at 60µA, the site was deemed no response.  Movement category, 
thresholds and their corresponding locations were recorded for each animal’s caudal 
forelimb area (CFA) and rostral forelimb area (RFA).  The resulting motor cortex map 
was then analyzed using pixel to area measuring software, and thresholds were sorted by 
category (distal and proximal) before analyzing averages for each animal. 
Histology 
Immediately following the cortical mapping procedure, animals were given an 
overdose of pentobarbital (Euthasol, 290mg pentobarbital sodium/mL) and perfused with 
0.1M phosphate buffer solution, followed by 4% paraformaldehyde solution.  Neural 
tissue was extracted and left to rest in 4% paraformaldehyde for at least 24 hours before 
being transferred to 30% sucrose solution.  Tissue was left in 30% sucrose for a minimum 
of 48 hours before being sectioned coronally at a thickness of 40µm on a microtome.  
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After collecting tissue sections into 0.1M phosphate buffer solution, every seventh 
section was mounted onto poly-l-lysine subbed slides for a sample approximately every 
240µm interval and left to air dry before staining.  Slides were stained with cresyl violet 
(for Nissl substance staining) and Myelin stains.  For every other section, ipsilesional and 
contralesional cortex areas were traced in imageJ and lesion volumes calculated. 
 
Statistics 
All data in this study were reported as the mean and standard error of the mean.  
Statistical significance was determined using a one-way analysis of variance (ANOVA) 
with Group as a between subject factor and subsequent Fisher’s Least Squares Difference 
(LSD)  post hoc tests. 
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CHAPTER 3 
RESULTS 
Motor Maps 
A One-Way ANOVA revealed a significant main effect of Group on total motor 
map area [F(2,12)=34.569; p<0.01].  Subsequent multiple comparisons revealed the 
Control animals to have significantly larger total motor maps than both the VNS+Stroke 
and Stroke animals. Further, VNS+Stroke animals had larger motor maps than the Stroke 
animals (Figure 5).  The same effect of Group was found for both the RFA 
[F(2,12)=5.893; p<0.05] and CFA [F(2,12)=23.881; p<0.01].  Further, a main effect of 
Group was also found for total movement threshold [F(2,12)=26.716; p<0.01], CFA-
Distal movement threshold [F(2,12)=8.605; p<0.05] and CFA-Proximal movement 
threshold [F(2,12)=24.544; p<0.01]. Stroke animals had significantly higher total, CFA-
Distal and CFA-Proximal movement thresholds than both the Control and VNS+Stroke 
animals (Figure 6).  There was no statistically significant difference between Control and 
VNS+Stroke movement thresholds on any of the three measures.  Most VNS+Stroke 
group animals had no movement responses throughout the entire RFA.  Thus, RFA 
movement thresholds were not compared between groups due to insufficient threshold 
data.   
Lesion Volume 
A one-way ANOVA revealed a significant main effect of Group on lesion volume 
[F(2,12)=34.569; p<0.01].  Subsequent multiple comparisons revealed the Stroke animals 
to have significantly larger lesion volumes than both the VNS+Stroke and Control 
animals (Figure 7). 
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Figure 4: Representative motor maps.  Representation of (ipsilesional) caudal forelimb 
area (CFA) and rostral forelimb area (RFA) of Control, Stroke, and VNS+Stroke groups.  
Proximal and distal forelimb movement sites were denoted with blue and green markers 
respectively.  No response sites were indicated by black markers. 
 
 
Figure 5: Average forelimb motor map areas for each group (A: Caudal forelimb area B: 
Total forelimb area). 
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Figure 6: Forelimb movement thresholds.  Forelimb movement thresholds as measured 
by ICMS (A: Caudal forelimb area (distal movements) B: Caudal forelimb area (proximal 
movements) C: Overall thresholds) 
 
Figure 7: Representative coronal sections for each group (Control, Stroke, and 
VNS+Stroke) to demonstrate lesion volume.  Sections were stained with cresyl violet and 
myelin stains. 
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Figure 8: Volumetric analysis of infarct size. Lesion volume estimation calculated by 
finding the difference in ipsilesional cortical volume and contralesional cortical volume. 
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CHAPTER 4 
DISCUSSION 
The aim of this project was to determine the effects of VNS had when applied 
daily during the 96 hours after an ischemic stroke.  This was accomplished by measuring 
the effects of 3 days of VNS on motor cortex map integrity and lesion volume.  By 
comparing these data sets for groups of Control, Stroke, and VNS+Stroke animals, we 
were able to observe the effects of VNS stimulation in preventing damage to tissue and 
helping to preserve motor map integrity. 
Animals in the VNS+Stroke group showed significantly smaller lesion volumes in 
comparison to animals in the stroke-only group.  Animals who received VNS also each 
exhibited significantly lower motor movement threshold than those of the stroke group.  
Additionally, though the motor map size of the VNS+Stroke group was significantly 
larger than the map size of the stroke-only animals.  While all animals in the stroke group 
measured no response across entire forelimb motor cortex (Figure 4), all animals in the 
VNS+Stroke group had at least one or more map sites that elicited a forelimb response.   
These results imply that the delivery of VNS within 48 hours post-stroke is able to 
help to preserve animals’ motor function and help mitigate lesion development.  To 
examine potential mechanisms responsible for these observations, we can first review 
what effects of the stroke occur during the timepoint at which we begin VNS.   
Biernaskie et al. (2001) demonstrated that stroke induced lesions continue to 
develop in size until 48 hours after the injury, thus lesions are still developing when VNS 
is applied within 48 hours following stroke.  Within the first few hours after a stroke, the 
neural tissue affected by the stroke can be categorized into two regions—regions of 
  17 
irreversible damage (the ischemic core) and regions of reversible damage (the tissue 
neighboring the ischemic core).  In the reversible damage zone tissue, the neurons are not 
directly impacted by the injury but do border the ischemic core and may also die 
(Murphy et al., 2009).  The smaller lesion size in the animals receiving VNS during this 
period of time suggests that VNS is able to halt or slow the lesion development and 
neuronal death that would otherwise normally occur in the progression of an ischemic 
stroke. 
To examine what might be driving these neuroprotective effects, we can examine 
what other changes are observed in the brain at this time point in the progression of 
stroke.  A compilation of human and animal data concluded that the changes observed in 
the brain after a stroke can be broken up into three time windows.  The first time window, 
ranging from the hours immediately after the stroke up to days after the stroke, have 
shown changes including cerebral blood flow (CBF), cerebral metabolic rate of oxygen 
(CMRO2) and inflammation (Cramer, 2004).   
It has been reported that in an ET-1 model of stroke, CBF levels in the ipsilesional 
cortex will return to levels matching the contralesional cortex at 16-22 hours after the 
injection of ET-1 (Biernaskie et al., 2001).  Recent work in the lab (Hillebrand, 2018) has 
demonstrated a profound decrease in both heart rate and regional cerebral blood flow 
immediately following VNS onset. The decrease is followed by an enduring increase in 
blood flow lasting beyond the cessation of stimulation.  However, by the time VNS was 
delivered (48 hours following ET-1 injection), CBF levels should have recovered from 
ET-1 induced vasoconstriction, but animals may still be in some way benefiting from the 
increased CBF levels. 
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It is also known that the vagus nerve’s cholinergic anti-inflammatory pathway can 
be activated via VNS.  While it is still uncertain what overall effect VNS induced 
activation of anti-inflammatory elements has on the overall inflammation (Mravec, 
2010), it has been reported that VNS is able to reduce inflammation levels in animals 
(Borovikova et al., 2000), and also has had some effects, though somewhat limited, on 
neurogenic inflammation levels in human patients (Kirchner et al., 2006). 
It is reasonable to postulate that either of these two effects of VNS could play a 
part in the protective effects observed in this experiment.  Further work using a different 
model of ischemia may help to determine the mechanism by which VNS confers 
neuroprotective effects.  
It is also important to note that although animals receiving VNS showed both 
spared tissue and preserved motor map integrity, the amount of animals’ motor map that 
was spared was smaller in comparison to the amount of tissue spared.  This suggests that 
while there is indeed more tissue spared, not all of the tissue is functional.  More of this 
tissue could potentially become functional again after motor rehabilitation.  Thus, there 
may be potential in VNS as a stroke treatment to address the period of time after current 
clinical treatment options are no longer effective, and before the damage has completely 
taken its course as a means of limiting damage.  VNS applied during this time may be 
worthwhile as a precursory measure before motor rehabilitation begins.  Further work 
repeating this experimental procedure with an added element of motor rehabilitation 
following the VNS treatment would serve to more thoroughly investigate the full 
potential of this treatment. 
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